Health and Healthcare
National Employee Morale Day At XenoPort (XNPT)
Published:
Last Updated:
Biotech firm XenoPort (XNPT) will lay-off half of its employees. The company lists 219 full-time workers.
On February 17, the FDA rejected a restless leg syndrome drug being developed by XenoPort and GlaxoSmithKline (GSK) because of a potential link to cancer found in rats. Six research firms downgraded the stock including DeutscheBank and Citigroup. XenoPort’s stock dropped from $20 to under $7 in a day.
To make shareholders feel better Ronald W. Barrett, Ph.D., XenoPort’s chief executive officer said, “We are fortunate to have a number of product candidates in clinical development as well as several other advanced preclinical compounds that can be developed.” But, there is apparently not enough potential in the candidates to keep the staff intact.
Dr. Barrett made $1.9 million last year, according to the company’s proxy. He had to fire a lot of people to cover that.
Douglas A. McIntyre
It’s Your Money, Your Future—Own It (sponsor)
Retirement can be daunting, but it doesn’t need to be.
Imagine having an expert in your corner to help you with your financial goals. Someone to help you determine if you’re ahead, behind, or right on track. With SmartAsset, that’s not just a dream—it’s reality. This free tool connects you with pre-screened financial advisors who work in your best interests. It’s quick, it’s easy, so take the leap today and start planning smarter!
Don’t waste another minute; get started right here and help your retirement dreams become a retirement reality.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
Our expert who first called NVIDIA in 2009 is predicting 2025 will see a historic AI breakthrough.
You can follow him investing $500,000 of his own money on our top AI stocks for free.